Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a ...
Net sales of $7.4 billion, an increase of 10.7%Net income of $239 million, a decrease of 25.8%Adjusted EBITDA1 of $776 million, a decrease of 10.6%Raising full year 2026 Organic Sales2 guidance range ...
US drug pricing policy and Congressional Budget Office (CBO) model of the Build Back Better Act examining pharmaceutical R&D ...
Everything is in place for resolving the issues surrounding the rights of the Hungarian minority in Transcarpathia according to the Ukrainian leadership—an area where no progress was made under Orbán.